There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Yahoo Finance discussed the stock recently as it posted Bionano to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference.
This NASDAQ-listed company operates within the Medical Instruments & Supplies industry segment, falling under the Healthcare sector. The current market capitalization of Bionano Genomics Inc is $47.77M. A total of 1.22 million shares were traded on the day, compared to an average of 0.67 shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, BNGO has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 7 BUYs and 2 SELLs from insiders. Insiders purchased 775,789 shares during that period but sold 91,637.
In the most recent transaction, Mamuszka Hannah bought 65,789 shares of BNGO for 0.76 per share on Jun 13. After the transaction, the Director now owns 65,789 company shares. In a previous transaction on May 16, Holmlin R. Erik bought 15,000 shares at 0.64 per share. BNGO shares that President and CEO owns now total 806,474.
Among the insiders who bought shares, Stewart Christopher P. acquired of 50,000 shares on May 12 at a per-share price of $0.67. This resulted in the Chief Financial Officer holding 281,373 shares of BNGO after the transaction.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for BNGO in the last 3 months, the mean price target is $9.00 with high estimates of $14.00 and low estimates of $6.00. In terms of 52-week highs and lows, BNGO has a high of $17.10 and a low of $1.04.
As of this writing, BNGO has an earnings estimate of -$0.87 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.75 per share and a lower estimate of -$1.01. The company reported an EPS of -$1.24 in the last quarter, which was -20.40% lower than expectations of -$1.03.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. BNGO’s latest balance sheet shows that the firm has $250.61M in Cash & Short Term Investments as of fiscal 2021. There were $10.70M in debt and $21.84M in liabilities at the time. Its Book Value Per Share was $3.37, while its Total Shareholder’s Equity was $337.12M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BNGO is Buy with a score of 4.50.